Benzinga | Jun 14, 2021 07:01AM EDT

Anavex Life Sciences Highlights Publication In Medical Journal Elucidating the Mechanism of ANAVEX2-73 And ANAVEX3-71 Related To The Treatment Of Alzheimer's Disease

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today reported that ANAVEX(r)2-73 (blarcamesine) and ANAVEX(r)3-71 (AF710B) are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets, titled "The emerging role of the sigma-1 receptor in autophagy: Hand-in-hand targets for the treatment of Alzheimer's".1